OncoMatch/Clinical Trials/NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Is NCT07114315 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including AK112 and AK130 for pancreatic cancer.
Treatment: AK112 · AK130 — This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: TGF-β inhibitor
Prior systemic therapy with either TGF-β inhibitors or anti-angiogenic agents.
Cannot have received: anti-angiogenic agent
Prior systemic therapy with either TGF-β inhibitors or anti-angiogenic agents.
Lab requirements
Blood counts
Kidney function
Liver function
Has adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify